AzTrials
AzTrials

MigrainePhase 3CONQUERNCT03559257

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

A Phase 3 study testing Galcanezumab in people with Migraine, run by Eli Lilly and Company at 69 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Migraine
What is being tested?
Galcanezumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
463 participants
Where
69 sitesin 13 countries
Study dates
31 Jul 2018to 19 Sep 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have a diagnosis of migraine or chronic migraine.
  • History of migraine headaches at least 1 year prior to screening, with onset prior to age 50.
  • History of at least 4 migraine headache days and at, with at least 1 headache-free day per month on average within the past 3 months.
  • Have documentation of 2 to 4 migraine preventive medication category failures due to inadequate efficacy or tolerability, in the past 10 years.

Who cannot join

  • Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.
  • Current use or prior exposure to galcanezumab or another calcitonin gene-related peptide (CGRP) antibody.
  • History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine).
  • Pregnant or nursing.

Trial locations and contacts

69 sites in 13 countries.

69 sites in 13 countries

United States18 sites
  • Albuquerque Clinical Trials

    Albuquerque, New Mexico, 87102

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania, 18104

  • Michigan Head, Pain and Neurological Institute

    Ann Arbor, Michigan, 48104

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007-4209

  • Boston Clinical Trials

    Boston, Massachusetts, 02131

  • PharmQuest

    Greensboro, North Carolina, 27408

  • Clinical Research Institute

    Minneapolis, Minnesota, 55402

  • Coastal Carolina Research Center, Inc.

    Mt. Pleasant, South Carolina, 29464

  • Healthy Perspectives Innovative Mental Health Services, PL

    Nashua, New Hampshire, 03060

  • Health Research of Hampton Roads Inc

    Newport News, Virginia, 23606

  • Sensible Healthcare

    Ocoee, Florida, 34761

  • 21st Century Neurology

    Phoenix, Arizona, 85004

  • Rochester Clinical Research, Inc.

    Rochester, New York, 14609

  • Foothill Family Clinic

    Salt Lake City, Utah, 84109

  • Medical Center for Clinical Research

    San Diego, California, 92108

  • University of South Florida

    Tampa, Florida, 33612

  • Bio Behavioral Health

    Toms River, New Jersey, 08755

  • Renstar Medical Research

    Wesley Chapel, Florida, 33544

Other trials in United States

Japan12 sites
  • Doi Clinic Internal Medicine Neurology

    Hiroshima, 730-0031

  • Tanaka neurosurgical clinic

    Kagoshima, 892-0844

  • Medical corporation Shinmatsudakai Atago Hospital

    Kochi, Kochi, 780-0051

  • Tatsuoka Neurology Clinic

    Kyoto, 600-8811

  • Ooba Clinic for Neurosurgery & Headache

    Ōita, 870-0831

  • Tominaga Hospital

    Osaka, 5560017

  • Higashi Sapporo Neurology and Neurosurgery Clinic

    Sapporo, Hokkaido, 003-0003

  • Sendai Headache and Neurology Clinic

    Sendai, Miyagi, 982-0014

  • Dokkyo Medical University Hospital

    Shimotsuga-Gun, Tochigi, 321 0293

  • Fukuuchi Pain Clinic

    Shinjuku-ku, Tokyo, 160-0017

  • Shimoda Neurology Clinic

    Tottori-shi, Tottori, 680-0045

  • Takase internal medicine clinic

    Toyonaka-shi, Osaka, 560-0012

Other trials in Japan

Czechia6 sites
  • Neurologicka ambulance, Neurologie Brno s.r.o.

    Brno, 616 00

  • Brain-Soultherapy s.r.o

    Kladno, 27201

  • Clintrial, s.r.o.

    Prague, Hl. M. Praha, 100 00

  • DADO MEDICAL, s.r.o.

    Prague, 120 00

  • Neurologicka ordinace

    Prague, 160 00

  • Institut Neuropsychiatricke Pece

    Prague, 18600

Other trials in Czechia

Spain6 sites
  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907

  • Hospital Universitario Marques De Valdecilla

    Santander, Cantabria, 39008

  • Hospital Clínico Universitario de Valencia

    Valencia, 46010

  • Hospital Universitario La Fe de Valencia

    Valencia, 46026

  • Hospital Clinico Universitario de Valladolid

    Valladolid, 47010

Other trials in Spain

Germany5 sites
  • Charité Universitätsmedizin Berlin

    Berlin, 10117

  • Praxis Dr. Philipp Stude

    Bochum, North Rhine-Westphalia, 44787

  • Universitätsklinikum Essen

    Essen, 45147

  • Universitätsklinikum Jena

    Jena, Thuringia, 07747

  • DRK-Kliniken Nordhessen

    Kassel, Hesse, 34121

Other trials in Germany

South Korea4 sites
  • Nowon Eulji Medical Center, Eulji University

    Seoul, 01830

  • Seoul National University Hospital

    Seoul, 03080

  • Kangbuk Samsung Hosp

    Seoul, 03181

  • Severance Hospital Yonsei University Health System

    Seoul, 120-792

Other trials in South Korea

Belgium3 sites
  • Algemeen Ziekenhuis St Jan Brugge

    Bruges, 8000

  • Universitair Ziekenhuis Brussel

    Brussels, 1090

  • Universitair Ziekenhuis Gent

    Ghent, B-9000

Other trials in Belgium

Canada3 sites
  • Aggarwal and Associates Ltd

    Brampton, Ontario, L6T 0G1

  • Okanagan Clinical Trials

    Kelowna, British Columbia, V1Y 1Z9

  • DIEX Recherche Sherbrooke, Inc

    Sherbrooke, Quebec, J1H 1Z1

Other trials in Canada

France3 sites
  • CHRU de Lille- Hôpital Roger Salengro

    Lille, Cedex, 59037

  • Hôpital de Cimiez

    Nice, 06000

  • CHU St Etienne Hopital Nord

    Saint-Etienne, 42000

Other trials in France

Hungary3 sites
  • SE Neurologiai Klinika

    Budapest, 1083

  • Orszagos Idegtudomanyi Intezet

    Budapest, 1145

  • Valeomed Kft.

    Esztergom, Komárom-Esztergom, 2500

Other trials in Hungary

United Kingdom3 sites
  • Hull Royal Infirmary

    Hull, East Yorkshire, HU3 2JZ

  • Kings College Hospital

    London, Greater London, SE5 9RS

  • St Thomas's Hospital

    London, SE1 7EH

Other trials in United Kingdom

Netherlands2 sites
  • Canisius-Wilhelmina Ziekenhuis

    Nijmegen, Gelderland, 6532 SZ

  • Isala Klinieken

    Zwolle, 8025 AB

Other trials in Netherlands

Puerto Rico1 site
  • Instituto de Neurologia Dra. Ivonne Fraga

    San Juan, PR, 00918

Other trials in Puerto Rico

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

Conditions
Migraine
Being tested
Galcanezumab, Placebo
Keywords
prevention, prophylaxis, headache, treatment-resistant, treatment resistant
Medical subject headings
Migraine Disorders, Headache

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GalcanezumabDrug

    Also called LY2951742

    Administered SC.

  • PlaceboDrug

    Administered SC.

Study groups in NCT03559257
Study groupRoleWhat they receive
GalcanezumabExperimentalGalcanezumab administered subcutaneously (SC).
Receives: Drug: Galcanezumab
PlaceboPlacebo comparatorPlacebo administered SC.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days

    Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean is derived from the average of months 1 to 3 from mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.

    Measured: Baseline, Month 1 through Month 3

Secondary outcomes (18)
  1. Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days in Participants With Episodic Migraine

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.

    Measured: Baseline, Month 1 through Month 3

  2. Percentage of Participants With ≥50% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  3. Percentage of Participants With Episodic Migraine With ≥50% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with at least a 50% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  4. Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1)

    MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.

    Measured: Baseline, Month 3

  5. Mean Change From Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality of Life Questionnaire Version 2.1 (MSQ v2.1) in Participants With Episodic Migraine

    MSQ v2.1 is a health status instrument, with a 4-week recall period, developed to address physical and emotional limitations of specific concern to individuals with migraine. Addressing the impact of migraine on work or daily activities, relationships with family \& friends, leisure time, productivity, concentration, energy, tiredness \& feelings. It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);\&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6),\& are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After the total raw score is computed for each domain, they are transformed to a 0-100 scale with higher scores indicating a better health status \& a positive change in scores reflecting functional improvement.

    Measured: Baseline, Month 3

  6. Percentage of Participants With Episodic Migraine With ≥75% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  7. Percentage of Participants With Episodic Migraine With 100% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  8. Percentage of Participants With ≥75% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with at least a 75% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  9. Percentage of Participants With 100% Reduction From Baseline in Monthly Migraine Headache Days

    MHD: A calendar day on which a migraine headache or probable migraine headache occurred.

    Overall mean percentage across months 1 through 3 of patients with 100% reduction in monthly MHDs from baseline using a categorical pseudo likelihood-based repeated measures model for binary responder indicator with fixed, categorical effects of treatment, month, treatment by month, and continuous, fixed covariate of baseline monthly MHD.

    Measured: Baseline, Month 1 through Month 3

  10. Overall Mean Change From Baseline in the Number of Monthly Days With Acute Headache Medication Use

    Overall mean is derived from the average of months 1 to 3 from Mixed model repeated measures (MMRM) model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.

    Measured: Baseline, Month 1 through Month 3

  11. Overall Mean Change From Baseline in the Number of Monthly Headache Days

    Headache Day: A calendar day on which any type of headache occurred (including migraine, probable migraine, and non-migraine headache).

    Overall mean is derived from the average of months 1 to 3 from MMRM model. Least square (LS) Mean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, and baseline by month as fixed effects.

    Measured: Baseline, Month 1 through Month 3

  12. Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score

    The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missed or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. LS mean was calculated using analysis of covariance (ANCOVA) with last observation carried forward (LOCF), with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

  13. Mean Change From Baseline in the 4-item Migraine Interictal Burden Scale (MIBS-4)

    MIBS-4 is a self-administered scale that measures the burden related to headache in the time between attacks. The instrument consists of 4 items that address disruption at work and school, diminished family and social life, difficulty planning, and emotional difficulty. The questionnaire specifically asks about the effect of the disease over the past 4 weeks on days without a headache attack. Response options include: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each responses associated numerical score are summed across all 4 items resulting in a total score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none, 1-2 mild, 3-4 moderate, and >5 severe. LS mean was calculated using MMRM model with fixed effects of treatment, pooled country, baseline migraine frequency category, month, treatment by month as fixed effects.

    Measured: Baseline, Month 3

  14. Mean Change From Baseline in the Work Productivity and Activity Impairment Questionnaire (WPAI)

    The WPAI Questionnaire is a patient-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores are calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores are calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

  15. Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S)

    The PGI-S is a patient-rated instrument that measures illness severity. For this study, the patient was instructed as follows: "Considering migraine as a chronic condition, how would you rate your level of illness?" The PGI-S includes a range of possible responses, from 1 ("normal, not at all ill") to 7 ("extremely ill"). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

  16. Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (US)

    EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state. LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

  17. Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - Health State Index (UK)

    EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the UK algorithm (-0.594 to 1). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

  18. Mean Change From Baseline in the European Quality of Life Questionnaire 5 Dimensions 5 Levels (EQ-5D-5L) - VAS Score

    EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. . The second part is assessed using a visual analog scale (VAS) on which the patient rates their perceived health state, ranging from 0 (the worst health you can imagine) to 100 (the best health you can imagine). LS mean was calculated using ANCOVA with LOCF with baseline, pooled country, baseline migraine frequency category, and treatment as fixed effects.

    Measured: Baseline, Month 3

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2018
  2. Study start31 Jul 2018
  3. Primary completion19 Jun 2019
  4. Study completion19 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
463 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03559257
Sponsor's protocol ID
16670
Other IDs
I5Q-MC-CGAW, 2018-000600-42, 2018
Acronym
CONQUER
Status last verified
Oct 2019
First submitted
6 Jun 2018
Last updated
8 Jul 2020
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Publications

  • Lampl C, Lipton RB, Lipsius S, Ford JH, Dell'Agnello G, Viktrup L, Buse DC. Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a post hoc analysis from a phase 3 migraine prevention study. Front Neurol. 2026 Jun 5;17:1808619. doi: 10.3389/fneur.2026.1808619. eCollection 2026.

    PubMed 42327799
  • Ford JH, Ye W, Ayer DW, Mi X, Bhandari S, Buse DC, Lipton RB. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine. J Patient Rep Outcomes. 2023 Apr 4;7(1):34. doi: 10.1186/s41687-023-00552-4.

    PubMed 37016181
  • Ailani J, Andrews JS, Tockhorn-Heidenreich A, Wenzel R, Rettiganti M. Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis. Adv Ther. 2022 Oct;39(10):4544-4555. doi: 10.1007/s12325-022-02233-y. Epub 2022 Aug 5.

    PubMed 35930126
  • Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache. 2022 Feb;62(2):198-207. doi: 10.1111/head.14257. Epub 2022 Jan 25.

    PubMed 35076090
  • Tepper SJ, Ailani J, Ford JH, Nichols RM, Li LQ, Kemmer P, Hand AL, Tockhorn-Heidenreich A. Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER). Clin Drug Investig. 2022 Mar;42(3):263-275. doi: 10.1007/s40261-021-01115-5. Epub 2022 Jan 18.

    PubMed 35041159
  • Okonkwo R, Tockhorn-Heidenreich A, Stroud C, Paget MA, Matharu MS, Tassorelli C. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study. J Headache Pain. 2021 Sep 30;22(1):113. doi: 10.1186/s10194-021-01322-7.

    PubMed 34592919
  • Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM, Stroud C, Tockhorn-Heidenreich A, Detke HC. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Adv Ther. 2021 Nov;38(11):5465-5483. doi: 10.1007/s12325-021-01911-7. Epub 2021 Sep 20.

    PubMed 34542830
  • Citrome L, Sanchez Del Rio M, Dong Y, Nichols RM, Tockhorn-Heidenreich A, Foster SA, Stauffer VL. Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. Adv Ther. 2021 Aug;38(8):4442-4460. doi: 10.1007/s12325-021-01848-x. Epub 2021 Jul 15.

    PubMed 34264500
  • Kuruppu DK, Tobin J, Dong Y, Aurora SK, Yunes-Medina L, Green AL. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. BMC Neurol. 2021 Apr 23;21(1):175. doi: 10.1186/s12883-021-02196-7.

    PubMed 33892641
  • Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021 Mar 25;22(1):15. doi: 10.1186/s10194-021-01230-w.

    PubMed 33765912
  • Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020 Oct;19(10):814-825. doi: 10.1016/S1474-4422(20)30279-9. Epub 2020 Sep 16.

    PubMed 32949542

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Galcanezumab in people with Migraine, run by Eli Lilly and Company at 69 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 69 sites in United States, Japan, Czechia, Spain, Germany and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (time frame: Baseline, Month 1 through Month 3). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03559257, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in